Quadriga BioSciences is focused on developing innovative oncology therapeutics, particularly through its lead product, QBS72S. This novel chemotherapeutic agent utilizes the L-type Amino Acid Transporter 1 (LAT1) to penetrate the blood-brain barrier and target rapidly growing cancer cells. By mimicking the structure of aromatic amino acids, QBS72S is designed to act as a "Trojan Horse," allowing it to be transported into cancer cells where it forms DNA interstrand cross-links, ultimately leading to cell death. This targeted approach aims to overcome significant barriers in cancer treatment, particularly for brain tumors and other malignancies that are difficult to treat due to their location.

In addition to QBS72S, Quadriga is advancing its research pipeline, which includes various clinical trials assessing the efficacy of this agent in treating conditions such as glioblastoma and brain metastases from breast cancer. The company is committed to leveraging its expertise in oncology drug development to bring forward novel therapies that can improve outcomes for patients with challenging cancers. Quadriga's leadership team comprises experienced professionals with extensive backgrounds in drug development, further enhancing the company's potential to make significant contributions to cancer therapeutics.

United States

Quadriga BioSciences, Inc. is a privately-held pharmaceutical company developing proprietary targeted cancer therapies. Their technology is based on the development of novel, first-in-class chemotherapeutic agents that are specifically designed to transport chemotherapeutic agents across the blood-brain barrier to target cancer. The company's leadership, founders, scientific advisory board, and principal investigators are world-renowned oncology experts.

Quadriga BioSciences

Company Details